Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Wanbury Ltd

WANBURY.NS ✓ COMPLIANT ☆ Track — members

NSE India · Healthcare · Pharmaceuticals ·

India Micro Cap Analyst: N/A

Last Close

$2.74

▲ +4.08%

Market Cap $95.75M · Vol 341.96K

Key Metrics

P/E Ratio

15.13

FWD: N/A

Market Cap

$95.75M

Micro Cap

Div Yield

N/A

Annual dividend

EPS Growth

N/A

YoY

RSI (14)

22.08

Momentum

Beta

1.34

vs Market

52W High

$3.76

26.55% below

52W Low

$1.69

55.91% above

Volume

341.96K

Avg 778.30K

P/B

5.37

Price-to-book

ROE

N/A

Return on equity

Free Float

48.69%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Wanbury Ltd (WANBURY.NS) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does WANBURY.NS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+2.51%

-22.22%

+1.08%

+2.64%

YTD

+15.34%

+3.73%

+337.98%

+212.62%

Financials & Valuation

TTM · Annual

Total Revenue	$69.58M
Net Income	$7.08M
Revenue Growth (YoY)	+1.47%
Gross Margin	55.28%
Operating Margin	14.22%
Net Profit Margin	10.17%
ROE	N/A
ROA · ROIC	12.84% · 32.82%

P/E Ratio	15.13
Forward P/E (FY1)	N/A
PEG Ratio	0.08
P/S	1.10
P/B	5.37
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	34.97M

Technical Indicators

50-Day SMA	$3.01
200-Day SMA	$2.67
RSI (14)	22.08
Beta	1.34
52-Week High	$3.76
52-Week Low	$1.69

Volume Today	341.96K
Avg Daily Volume (30D)	778.30K
Relative Volume	0.44x
Volatility (10D)	56.07
Volatility (30D)	57.07
Free Float	48.69%

Analyst Consensus

N/A

Current Price $2.74

Mean Target N/A

52W Low$1.69 52W High$3.76

Current

Target

$1.69 $3.76

Current Analyst target

· 0 analysts

Identifiers

ExchangeNSE India

FIGIBBG001S849D1

ISININE107F01022

CountryIndia

Sub-IndustryGeneric Pharmaceuticals

Earnings DateN/A

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

SUNPHARMA.NS Sun Pharmaceutical Industries Ltd -0.10% 4578.T Otsuka Holdings Co Ltd -3.26% CIPLA.NS Cipla Ltd -0.60% ZYDUSLIFE.NS Zydus Lifesciences Ltd -2.75% RICHTER.BU Richter Gedeon Vegyeszeti Gyar Nyrt +1.56%

Company Profile

Wanbury Limited is an India-based pharmaceutical company with a presence in the active pharmaceutical ingredients (APIs) global market and domestic branded formulations. The Company is engaged in the business of pharmaceutical and related activities, including research. Its API products include Metformin, Metformin Dc, Tramadol, Sertraline, Diphenhydramine HCL, Diphenhydramine Citrate, Mefenamic Acid, Paroxetine Hemihydrate, Promethazine, Glucosamine, Clopidogrel, Levetiracetam and Carvedilol Phosphate Monohydrate. In formulations, the Company has a presence across various therapeutic categories, such as cough and cold solutions, gynecology, orthopedics, nutraceuticals, gastrointestinal, anti-inflammatory and analgesics. The Company is also focused on the development of products like ketamine, rivaroxaban, montelukast, sitagliptin and a few others to reduce dependency on metformin and sertraline. The Company has facilities in Tanuku, Andra Pradesh, and Patalganga, Maharashtra.